The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals announced yesterday.

The Food and Drug Administration has authorized emergency use of the therapy for people at high risk of progressing to severe COVID-19 or hospitalization. The company plans to ask the agency to expand the EUA to include COVID-19 prevention.  

Related News Articles

Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…
Headline
In this AHA video for Mother’s Day, part of AHA’s #MyWhy social media campaign, a pregnant health care worker explains why she chose to get…
Headline
Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose…
Headline
AHA yesterday urged the Department of Health and Human Services to extend the deadline for hospitals and other health care providers to use their COVID-19…
Blog
In this update to his September 2020 blog post, Mike Schiller, senior director of supply chain for the AHA’s Association for Health Care Resource and Materials…
Headline
The AHA today donated to UNICEF to help hospitals and communities fight a devastating surge in COVID-19 cases in India. UNICEF is rushing urgently needed…